Stryker Corporation is a leading medical technology company that specializes in designing, manufacturing, and marketing innovative products and services for healthcare professionals and patients
The company offers a diverse range of medical devices, including surgical equipment, orthopedic implants, neurotechnology, and surgery assistance products. Stryker focuses on advancing healthcare through cutting-edge technology and solutions that enhance patient care, improve surgical outcomes, and streamline hospital operations. With a commitment to innovation and quality, Stryker plays a pivotal role in the medical industry, helping healthcare providers deliver effective treatment and improve the quality of life for patients around the world.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at medical devices & supplies - diversified stocks, starting with Stryker (NYSESYK).
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - diversified stocks fared in Q4, starting with Baxter (NYSEBAX).
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Neogen (NASDAQNEOG) and its peers.
Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSESYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. NASDAQ: NARINASDAQNARI)
Portage, Michigan, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSESYK) will participate in Citi’s 2025 Unplugged Medtech and Life Sciences Access Day on Thursday, February 27, 2025 at Citigroup Headquarters, New York, New York.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Boston Scientific (NYSEBSX) and the best and worst performers in the medical devices & supplies - diversified industry.
Portage, Michigan, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSESYK) announced today that after 14 years of distinguished service, Allan Golston has notified the company that he will not stand for re-election at Stryker's 2025 Annual Meeting of Shareholders, which is expected to be held on May 8, 2025. Golston joined Stryker’s Board of Directors in 2011 and served as independent Lead Director from 2016 to 2022. He also served on the Governance and Nominating Committee and as Chair of the Compensation and Human Capital and Audit Committees. “We are grateful for Allan’s many contributions to the board over the years and thank him for his strategic guidance and steadfast support of our growth ambitions,” said Kevin Lobo, Chair and Chief Executive Officer, Stryker. “We thank Allan for his leadership and dedication in helping Stryker advance our mission of making healthcare better.” Golston has served as the President, United States Program for the Bill & Melinda Gates Foundation since 2006, and as Chief Financial and Administrative Officer of the Bill & Melinda Gates Foundation from 2000 to 2006. He is also a director of Harley-Davidson, Inc., a manufacturer of motorcycles and accessories. Golston has extensive experience in auditing, finance and the healthcare industry. He is a certified public accountant and has held hospital finance executive positions. In his service to the Gates Foundation, he has contributed to the strategic formation and operation of successful initiatives to provide healthcare, education and other human needs, all of which gave him an understanding that assisted Stryker in its global efforts to meet the needs of patients and caregivers. About Stryker
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSEABBV), saying it's “just a gem” and a “winner.” He added, “I can't believe the stock dropped so much.”
Portage, Michigan, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSESYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable April 30, 2025 to shareholders of record at the close of business on March 31, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter.
Medical technology company Stryker (NYSESYK) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 10.7% year on year to $6.44 billion. Its non-GAAP profit of $4.01 per share was 3.5% above analysts’ consensus estimates.
